Mergers and acquisitions
The latest mergers and acquisitions news from across all sectors of the chemical and pharmaceutical industries, from the Royal Society of Chemistry's magazine, Chemistry World
-
BusinessSanofi spins out its consumer healthcare business
US-based investment firm takes controlling stake in Opella, while France’s government moves to ensure the company remains in the country
-
BusinessAdnoc to buy Covestro, continuing expansion into polymers
€15 billion deal sees Gulf oil producer looking to future growth beyond fuels
-
NewsWeight-loss drugmakers bet billions on boosting supplies
Eli Lilly and Novo Nordisk invest to expand in-house manufacturing of GLP-1 drugs
-
-
BusinessPan-cancer approval shows huge potential for antibody–drug conjugates
Enhertu gains approval based on gene expression rather than tumour location
-
BusinessBig deals confirm renewed interest in radiopharmaceuticals
Acquisitions of RayzeBio and Point Biopharma highlight the potential of targeting radioactivity directly to tumour cells
-
BusinessNovo Holdings to buy contract manufacturer Catalent for $16.5 billion
Parent firm will then sell on three manufacturing sites to Novo Nordisk to boost capacity for diabetes and weight loss drugs
-
BusinessIllumina to give up Grail as competition appeals fail
Sequencing giant will sell off its former spin-out in accordance with regulator orders
-
BusinessChemicals roundup 2023
Chemical companies entered cost-cutting mode in a year dominated by overcapacity and slow demand
-
BusinessPharmaceuticals roundup 2023
Regulatory and pricing reforms have topped industry agendas in 2023, while weight loss drugs surged and Covid-19 therapies waned
-
BusinessDanaher completes $5.7 billion Abcam acquisition
Deal proceeded despite significant opposition from founder and ex-chief Jonathan Milner
-
BusinessBuilding the support infrastructure we wish we’d had
Harry Destecroix of Science Creates is the 2023 Chemistry World Entrepreneur of the Year
-
BusinessExxonMobil to buy Pioneer for US shale oil dominance
$59 billion deal sees Exxon double its shale oil and gas production
-
BusinessBiogen to cut 1000 more jobs by 2025
Biotech giant has also agreed to buy Reata Pharmaceuticals for $7.3 billion
-
BusinessIllumina’s Grail quest results in epic fine
EU and US competition authorities object to firms completing merger without approval
-
BusinessUS trade regulator sues to block Amgen–Horizon merger
Federal Trade Commission has concerns that union will allow Amgen to stifle potential competition for Horizon’s drugs
-
BusinessPfizer to buy cancer biotech Seagen for $43 billion
Antibody-drug conjugate specialist will fill Pfizer’s cancer pipeline
-
BusinessChemicals industry roundup 2022
Russia’s invation of Ukraine mounted further pressure onto already strained supply chains
-
BusinessPharmaceuticals roundup 2022
Following the huge success of vaccines and treatments for covid-19, companies are upping their investment in R&D and dealmaking
-
BusinessHaleon emerges from GSK consumer healthcare spin-off
Split illustrates move towards narrower focus in pharmaceuticals